Partner A: $189 per vial. Partner B: $149 per vial. Partner B wins.
Until you notice Partner A is 2.5 mg/mL for a 28-day protocol and Partner B is 2.5 mg/mL for 14 days, plus a $12 processing fee and $29 shipping on every order. Now Partner B costs more per patient-month. That is the Friday spreadsheet trap national telehealth ops teams describe when they say they need to compare pricing from different pharmacy partners.
This guide shows how clinic ops and finance leads compare 503A pharmacy pricing apples to apples: same strength, same supply duration, every fee row visible, landed cost settled before you quote a member.
Who this is for
This article is for clinic ops leads, pharmacy coordinators, and founder-led telehealth finance owners who evaluate 503A compounders and set cash-pay member pricing.
You are not the audience if you are a patient shopping for the lowest GLP-1 price or a prescriber asking about clinical dosing. This is coordinator-side economics content only. It is not medical advice.
The scene ops teams describe on vendor calls
On a recent discovery call with a national telehealth team, ops walked through the same pricing friction we hear from scaled weight-loss and hormone brands:
- “Are these base prices?”
- “Shipping fee… processing fee…”
- “How much would it be a month, two months, worth of medication?”
- “We need to compare currently the pricing from our different pharmacy partners.”
They were not asking for a feature tour. They needed credible landed math so they could quote subscribers and pick partners without a three-day spreadsheet rebuild every quarter.
We need apples-to-apples landed cost per patient, for the same strength and supply duration, before we commit.
What apples-to-apples 503A pricing actually means
Apples-to-apples 503A pricing means every partner quote is expressed as landed cost for the same patient-period: medication at a defined strength and concentration, for a defined number of days, plus every fee that hits checkout.
A headline vial price is not a comparison. A landed row is.
| Comparison element | What to lock | Why mismatches fool teams |
|---|---|---|
| Strength | Same API dose per vial (e.g., 2.5 mg/mL semaglutide) | Different concentrations change how many injections a vial covers |
| Supply duration | Approximate days of supply (28 vs 56) | A cheaper vial that lasts half as long costs more per month |
| Fees | Facilitation, processing, shipping per order | Base price winners often lose after checkout |
If any row drifts between quotes, you are comparing citrus to stone fruit, not apples to apples.
The minimum comparison table (strength, supply, fees)
Build every partner column on these rows before you rank vendors:
| Row | Partner A | Partner B | Partner C |
|---|---|---|---|
| Medication + strength | Semaglutide 2.5 mg/mL | Semaglutide 2.5 mg/mL | Semaglutide 2.5 mg/mL |
| Concentration / package | 1 mL vial | 2 mL vial | 1 mL vial |
| Supply duration (approx. days) | 28 days | 28 days (verify SIG) | 56 days |
| Base medication price | $165 | $149 | $189 |
| Facilitation / platform fee | $0 (bundled in drug) | $8 disclosed | $0 (bundled in drug) |
| Processing | $12 | $0 | $15 |
| Shipping | $29 flat | $19 | $29 flat |
| Estimated landed cost | $206 | $176 | $233 |
| Landed cost per 28 days | $206 | $176 | $116.50 |
Partner B looked cheapest on base price. Partner C looked expensive on vial price. Normalized to the same 28-day period, the ranking flips.
That is the worksheet your finance lead actually needs.
Full comparison chart: nine columns every whale asks for
When ops teams run a formal partner evaluation, use the same column set field teams send on whale follow-ups:
| Column | Example (semaglutide) |
|---|---|
| Medication name | Semaglutide |
| Strength | 2.5 mg/mL |
| Concentration | 1 mL vial |
| Approximate days of supply | 28 |
| Base medication price | $165 |
| Facilitation fee | $8 (disclosed) or “bundled” |
| Processing | $12 |
| Shipping | $29 |
| Estimated landed cost | $214 |
No partner name column required for internal math. Add volume and card vs ACH mix only when you are tightening numbers, not when you are screening vendors for the first time.
Five mistakes that break 503A price comparisons
1. Comparing vial price without supply duration.
A $149 vial that covers 14 days loses to a $189 vial that covers 28 days. Always normalize to cost per patient-period.
2. Ignoring concentration drift.
2.5 mg/mL and 5 mg/mL are not interchangeable rows even when the drug name matches. Lock strength and concentration before fees.
3. Treating “base price” as landed cost.
If a rep says “that is the base price,” ask what processing and shipping add at checkout for your typical order size and geography.
4. Missing platform markup inside the drug line.
Some clinic portals bake 40 to 80 percent intermediary markup into the medication price. You only discover real COGS when the invoice lands. Pass-through catalogs show per-vial cost before you quote.
5. Quoting patients before the chart is done.
Wrong member pricing is harder to unwind than a slow vendor decision. Landed cost first, member quote second.
Questions to ask every 503A partner before you sign
Use this checklist on demos and reference calls:
- Is catalog price base medication only or landed cost?
- What processing fee applies per order vs per line?
- How does shipping work for your states (flat, tiered, cold chain)?
- Is there a facilitation or platform fee separate from the drug?
- Can you export the same strength and days of supply we order today?
- Does price in catalog match price at checkout?
If answers shift between catalog browse and checkout, your comparison chart is building on sand.
How landed cost connects to member pricing
Cash-pay clinics and telehealth brands set membership or per-fill pricing from COGS plus margin. When COGS is opaque, teams pad quotes “to be safe” and lose deals, or underprice and eat margin on every refill.
The outcome ops buyers name on calls is simple: quote patients from numbers you trust before checkout, not invoice archaeology after the order ships.
Field teams rank pricing transparency alongside support quality. A partner you cannot compare is a partner you cannot defend to your CFO or your members.
Where Fizy Health fits (honest framing)
Fizy Health is built for clinics that already use 503A compounders and need one ordering layer with economics you can see before you commit.
Pass-through pricing shows resolved per-vial 503A cost in the medication catalog and on every cart line. Checkout separates drug cost from disclosed facilitation before card authorization, so your comparison chart matches what coordinators see on screen.
That is the proof behind the outcome: landed cost per patient-period on the same strength and supply duration before you quote.
Telehealth-specific context lives on the telehealth ops page. Platform fee structure is on the pricing page.
Bottom line
You cannot compare 503A pharmacy partners on vial price alone. Lock strength, normalize supply duration, add every fee row, and rank landed cost per patient-period.
Build the chart before you quote members. The cheapest line on a PDF is rarely the cheapest month once checkout runs.